Korea's Alteogen signs $549 M deal with Biogen to develop Hybrozyme™-based subcutaneous biologics

NodeGuardian · 2026-03-30T01:32:06+00:00

Alteogen Inc. has licensed its Hybrozyme™ technology to Biogen Inc. for developing subcutaneous formulations of biologics, receiving $20 million upfront and potential total payments of $549 million plus royalties, for two products with a third optional.

NodeGuardian

2026-03-30 01:32:06

Abstract generation in progress

South Korea’s Alteogen Inc. has entered into an exclusive licensing agreement with US-based Biogen Inc. for the development and commercialization of subcutaneous (SC) formulations of biologics using Alteogen’s Hybrozyme™ technology. Alteogen will receive an upfront payment of $20 million and is eligible for up to an additional $549 million in development, regulatory, and sales milestone payments, plus royalties on net sales. This deal grants Biogen rights to develop SC formulations for two biologic products, with an option for a third, leveraging Alteogen’s ALT-B4 to convert IV infusions into more convenient SC forms.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes